1 We show that a portion of the TM2 domain regulates the sensitivity of beta subunit-containing rat neuronal nicotinic AChR to the ganglionic blocker mecamylamine, such that the substitution of 4 amino acids of the muscle beta subunit sequence into the neuronal beta4 sequence decreases the potency of mecamylamine by a factor of 200 and eliminates any long-term eects of this drug on receptor function. 2 The same exchange of sequence that decreases inhibition by mecamylamine produces a comparable potentiation of long-term inhibition by nicotine. 3 Inhibition by mecamylamine is voltage-dependent, suggesting a direct interaction of mecamylamine with sequence elements within the membrane ®eld. We have previously shown that sensitivity to TMP (tetramethylpiperidine) inhibitors is controlled by the same sequence elements that determine mecamylamine sensitivity. However, inhibition by bis-TMP compounds is independent of voltage. 4 Our experiments did not show any in¯uence of voltage on the inhibition of chimeric receptors by nicotine, suggesting that the inhibitory eects of nicotine are mediated by binding to a site outside the membrane's electric ®eld. 5 An analysis of point mutations indicates that the residues at the 6' position within the beta subunit TM2 domain may be important for determining the eects of both mecamylamine and nicotine in a reciprocal manner. Single mutations at the 10' position are not sucient to produce eects, but 6' 10' double mutants show more eect than do the 6' single mutants.
Introduction
The nicotinic acetylcholine receptor (AChR) of the neuromuscular junction remains the prototype for all synaptic transmitter-gated ion channels. However, the majority of the eects of smoking dosages of nicotine arise from the activation and/or subsequent inhibition (desensitization) of receptors on peripheral and central neurons which are homologous to the muscle-type receptor. Genes cloned from the nervous system, coding for proteins that are related to the subunits of the neuromuscular nicotinic AChR, include eight proteins designated as alpha subunits (a2 ± a9) and three non-alpha subunits, designated beta subunits (b2 ± b4) (for review see Papke, 1993) . Nicotinic receptors in the nervous system which show high anity binding of nicotine require the presence of at least one type of neuronal beta-subunit along with at least one type of neuronal alpha subunit. In these beta subunitcontaining receptors, the agonist binding sites are believed to be at the interface between the alpha and beta subunits, since both alpha and beta subunits in¯uence the sensitivity to agonists and antagonists (Hussy et al., 1994; Luetje & Patrick, 1991; Luetje et al., 1990; .
The predominant alpha subunit in the peripheral nervous system is a3. When the a3 subunit is co-expressed in Xenopus oocytes with b4, the major beta subunit of the peripheral nervous system, functional receptors are formed which may be taken to be at least a partial model for the receptors of autonomic ganglia (however, see also Conroy et al., 1992; Corriveau & Berg, 1993; Vernallis et al., 1993) .
This study provides insights into the structural basis for inhibitory eects of both nicotine and the ganglionic antagonist mecamylamine on a3-containing AChR. Mecamylamine is generally thought of as a noncompetitive antagonist (Bertrand et al., 1990; Francis & Papke, 1996; Stone et al., 1956; Varanda et al., 1985) and as such would produce inhibition by binding to sites other than the agonist activation sites. Nicotine on the other hand, is an agonist and may produce inhibition via enhanced desensitization, or alternatively, the inhibitory eects of nicotine may also arise from binding to sites similar or identical to those bound by noncompetitive inhibitors.
Noncompetitive inhibition can be classi®ed as either steric in nature, where the ligand directly blocks the conduction path, or allosteric, where the binding of the inhibitory ligand promotes the transition to, or stabilization of, non-conducting states. Steric inhibition is often referred to as open channel block, and such inhibition may be promoted by membrane hyperpolarization (i.e. voltage-dependent) if the steric binding site is within the membrane's electric ®eld. The eects of a noncompetitive inhibitor may be use-dependent for the onset of inhibition (i.e. require open channels) and then inhibition may persist if the ligand remains bound to the receptor.
Desensitization can be de®ned as a decrease in response that occurs in the continued presence of an agent that initially activates the receptor. It may be argued that true desensitization is promoted only by the binding of agonist at the same sites which promote activation (Katz & Thesle, 1957) . Such desensitization occurs as a ®rst-order process(s) with the rate constants for the conversion to desensitized states being faster for channels that have bound agonist and/or have opened. This gives the desensitization process an apparent concentration dependence. However, the interpretation of data obtained in the continued presence of agonist is complicated by the fact that agonists are known to bind to multiple sites on the receptor and decrease response via channel block or allosteric eects (Hussy et al., 1994; Rozental et al., 1989; Sine & Steinbach, 1984) . Moreover, desensitization and noncompetitive inhibition are tied together, at least in the sense that noncompetitive inhibitors have been documented to promote the same sort of high anity for agonists that is associated with desensitization (Changeux et al., 1987) . We have previously described how such noncompetitive inhibition by agonist can limit the eectiveness of nicotine and other agonists for the activation of a4b2 receptors, the predominant beta-subunit-containing receptor of the brain (Papke et al., 1997) .
In the present study we examine inhibition produced by the agonist nicotine and the ganglionic blocker mecamylamine. We determine the relative importance of sequence elements within the ion permeation pathway, and whether inhibition is aected by transmembrane voltage. Our results suggest that the pore-forming domain of the receptor is essential for determining sensitivity of nicotinic AChR to multiple and diverse forms of receptor inhibition.
Methods

Design of chimeric subunits
Hydrophobicity analysis and sequence comparison of the nicotinic subunits suggests that they all have similar basic structures, with a large amino-terminal extracellular domain containing the primary ligand binding sites followed by three hydrophobic domains, the primary intracellular domain, and a fourth transmembrane domain located downstream of the large intracellular segment, so that the carboxy-terminus of the protein is extracellular. Many lines of evidence have converged to indicate that the second transmembrane domain forms the ion channel (Changeux et al., 1987; Charnet et al., 1990; Cohen et al., 1992; Dennis et al., 1986; Giraudat et al., 1986; Labarca et al., 1995; Leonard et al., 1988; Revah et al., 1991) . This sequence of 20 amino acids (see below) contains essential elements to regulate the conductance, selectivity and desensitization of the channel. The TM2 (second transmembrane) domain of the muscle receptor subunits has been shown to also contain the binding site for local anaesthetics and other noncompetitive inhibitors. While much of the TM2 domain is likely to be within the membrane's electric ®eld, we have recently shown (Francis et al., 1998) that sequence elements deep within the TM2 domain also control the accessibility of sites outside the membrane's electric ®eld to the slowly dissociating ganglionic blocker bis-tetramethyl-piperidinyl sebacate (BTMPS).
The sequences of the TM2 domains of the relevant subunits are shown below. Adopting the terminology proposed by Leonard et al. (1988) , the 20 residues in the putative transmembrane sequence are identi®ed as 1' ± 20'. Initial experiments were conducted with wild-type subunits and two chimeric subunits designated b4 (b1TM2) and b1 (b4TM2). These subunits have been previously characterized (Francis et al., 1998) and contain reciprocal exchanges of 8 amino acids from positions 4' ± 11' (inclusive) in the TM2, shown in underline below. This amounts to total dierences of only 4 amino acids (at sites 4', 6', 7' and 10') between the wild-type and chimeric proteins.
For our experiments we used the rat cDNA clones for the neuronal receptors and the mouse muscle cDNA clones (Heinemann et al., 1986) . It is interesting to note that not only is the TM2 amino acid sequence 100% identical in the rat neuronal b2 and b4 subunits, but the TM2 amino acid sequences are 100% conserved between the rodent beta subunits and their human homologues.
Production of TM2 chimeras and sequencing
Chimeric genes were constructed by the method of overlap extension PCR (polymerase chain reaction) (Horton et al., 1989) . Clones were evaluated by both restriction analysis and sequencing through the PCR-generated region by the dideoxy chain termination method (Sanger et al., 1977) using the Sequenase 2.0 kit from United States Biochemical Corporation (Cleveland, OH, U.S.A.).
Construction of site-directed mutants
Site-directed mutagenesis was conducted with QuickChange 2 kits (Stratagene, LaJolla, CA, U.S.A.). In brief, two complimentary oligonucleotides were synthesized which contain the desired mutation¯anked by 10 ± 15 bases of unmodi®ed nucleotide sequence. Using a thermal cycler, Pfu DNA polymerase extended the sequence around the whole vector, generating a plasmid with staggered nicks. Each cycle built only o the parent strands, therefore there was no ampli®cation of misincorporations. After 12 ± 16 cycles, the product was treated with DpnI, which digested the methylated parent DNA into numerous small pieces. The product was then transformed into E. coli cells, which repaired the nicks. 
Preparation of RNA and expression in Xenopus oocytes
Mature (49 cm) female Xenopus laevis African toads (Nasco, Ft. Atkinson, WI, U.S.A.) were used as a source of oocytes. Prior to surgery, frogs were anaesthetized by placing the animal in a 2 g l 71 solution of MS222 (3-aminobenzoic acid ethyl ester). Eggs were removed from an incision made in the abdomen. Prior to the ligation of the ovarian tissue, the ovaries were sutured with 4 ± 0 silk. The incisions were disinfected with gentamicin, sutured with 4 ± 0 gut, and the animals were allowed to recover from the anaesthesia in a humid environment. Postoperative, animals were kept in isolation tanks and checked daily before being returned to the colony. No more than four survival surgeries were performed on any animal. After the ®nal surgery, animals were again anaesthetized in MS222 and euthanasia was accomplished by decapitation. Animal protocols are annually reviewed and approved by the university's Animal Use Committee.
After linearization and puri®cation of cloned cDNAs, RNA transcripts were prepared in vitro using the appropriate mMessage mMachine kit from Ambion Inc. (Austin, TX, U.S.A.). Harvested oocytes were treated with collagenase from Worthington Biochemical Corporation (Freehold, NJ, U.S.A.) for 2 h at room temperature in calcium-free Barth's solution (in mM NaCl 88, HEPES pH 7.6 10, MgS0 4 0.33, 0.1 mg 71 ml gentamicin sulphate). Subsequently, stage ®ve oocytes were isolated and injected with 50 nl each of a mixture of the appropriate subunit cRNAs following harvest. Recordings were made 1 ± 7 days after injection depending on the cRNAs being tested.
Electrophysiology
Oocyte recordings were made with a Warner Instruments (Hamden, CT, U.S.A.) OC-725C oocyte ampli®er and RC-8 recording chamber interfaced to a Macintosh personal computer. Data were acquired using Labview software (National Instruments) and ®ltered at a rate of 6 Hz. Oocytes were placed in a Warner recording chamber with a total volume of about 0.6 ml and perfused at room temperature by frog Ringer's solution (mM) NaCl 115, KCl 2.5, HEPES pH 7.3 10, CaCl 2 1.8) containing 1 mM atropine to inhibit potential muscarinic responses. A Mariotte¯ask ®lled with Ringer's solution was used to maintain a constant hydrostatic pressure for drug deliveries and washes. Drugs were diluted in perfusion solution and loaded into a 2 ml loop at the terminus of the perfusion line. A bypass of the drug-loading loop allowed bath solution to¯ow continuously while the drug loop was loaded, and then drug application was synchronized with data acquisition by using a 2-way electronic valve. The rate of bath solution exchange and all drug applications was 6 ml min 71 . Current electrodes were ®lled with a solution containing (mM) CsCl 250, CsF 250 and EGTA 100 and had resistances of 0.5 ± 2 MO. Voltage electrodes were ®lled with 3 M KCl and had resistances of 1 ± 3 MO. Oocytes with resting membrane potentials more positive than 730 mV were not used.
Experimental protocols and data analysis
Current responses to drug application were studied under twoelectrode voltage clamp at a holding potential of 750 mV unless otherwise noted. Holding currents immediately prior to agonist application were subtracted from measurements of the peak response to agonist. All drug applications were separated by a wash period of 5 min unless otherwise noted. At the start of recording, all oocytes received two initial control applications of ACh. Subsequent drug applications were normalized to the second ACh application in order to control for the level of channel expression in each oocyte. The second application of control ACh was used to minimize the aects of rundown that occasionally occurred after the initial AChevoked response. In order to measure residual inhibitory eects, an experimental application of ACh with inhibitor or of inhibitor alone was followed by a second application of ACh alone and compared to the pre-application control ACh response. Means and standard errors (s.e.mean) were calculated from the normalized responses of at least four oocytes for each experimental concentration.
For each of the receptor subtypes tested, a control ACh concentration was selected that was sucient to stimulate the receptors to a level representing a reasonably high value of p open at the peak of the response while minimizing rundown with successive ACh applications. For potent use-dependent inhibitors, we have found that such conditions are adequate to achieve maximal inhibition (Francis & Papke, 1996; . The control ACh concentration used for the a3-containing receptors was 100 mM. We noted that the ACh EC 50 for the a3b4(b1TM2) receptors (&75 mM) was somewhat reduced compared to a3b4 receptors (EC 50 &50 mM). This was presumably because at higher ACh concentrations, the inhibitory eects of ACh itself (see results) limited the maximum response obtainable, shifting the concentration response curve to the left. Speci®c concentrations for other receptor subtypes are as noted in the ®gures.
For concentration-response relations, data were plotted using Kaleidagraph 3.0.2 (Abelbeck Software; Reading, PA, U.S.A.), and curves were generated from the Hill equation (Luetje & Patrick, 1991) :
n where I max denotes the maximal response for a particular agonist/subunit combination, and n represents the Hill coecient. I max , n, and the EC 50 were all unconstrained for the ®tting procedures. Negative Hill slopes were applied for the calculation of IC 50 values. For experiments assessing voltage-dependence of inhibition, oocytes were initially voltage-clamped at a holding potential of 750 mV, and a control application of ACh alone was delivered. The holding potential was stepped to the designated voltage for 30 ± 60 s prior to either co-application of ACh with mecamylamine or the application of nicotine alone. Thirty to sixty seconds after the peak of the co-application response, voltage was stepped back to 750 mV, and residual inhibition was evaluated with a subsequent application of ACh alone after a 5 min wash period. The e-folding voltages were calculated by the method of Woodhull (1973) , from the exponential ®ts to the value Z-1 against voltage, where Z=control response divided by the response after the application of agonist and inhibitor.
Results
The sensitivity of neuronal nicotinic AChR to long term inhibition by mecamylamine can be regulated by sequence in the beta subunit transmembrane domain
The co-application of mecamylamine with 100 mM ACh produced a potent inhibition of a3b4 responses ( Figure 1A) , with an IC 50 of approximately 150 nM. In contrast, receptors containing the b4(b1TM2) chimeric subunit were 200 fold less sensitive to inhibition by mecamylamine (IC 50 &30 mM, Figure  1A ). In addition to lowering the potency of mecamylamine, the substitution of the muscle beta subunit sequence into b4 also produced a qualitative change in the nature of the inhibition. Speci®cally, a residual inhibition of a3b4 receptors was observed after the application of mecamylamine, while a3b4(b1TM2) receptors recovered fully following a 5 min wash period. The after-eects of mecamylamine are shown in Figure 1B , which shows the amplitude of control responses to ACh alone following the co-application of ACh and mecamylamine. The IC 50 for this form of inhibition of a3b4 receptors was approximately 1 mM. This persistent inhibition was use dependent, such that when 1 mM mecamylamine was applied in the absence of agonist, post-application ACh controls were 98+5% (n=4) of the pre-application controls.
The representative traces in Figure 2 illustrate the greater potency of mecamylamine for the inhibition of a3b4 receptors compared to a3b4(b1TM2) receptors. While 300 nM mecamylamine produced a greater than 50% inhibition of the a3b4 peak response, a 100 fold higher concentration of mecamylamine was required to produce similar inhibition of a3b4(b1TM2) receptors. The inserts in Figure 2 show the control and inhibited responses scaled to the same amplitude. Mecamylamine produced an accelerated time to peak in the a3b4 receptor responses (Table 1) , consistent with usedependent inhibition. Note that the ACh control responses of a3b4(b1TM2) receptors were accelerated compared to those obtained in a3b4 receptors (Figure 2 and Table 1 ). The responses of a3b4(b1TM2) receptors to mecamylamine coapplication were not signi®cantly faster than their respective controls. However, with the a3b4(b1TM2) receptors, but not the a3b4 receptors, a small relaxation out of an inhibited state could be seen as the drug concentrations fell in the chamber (arrow in Figure 2 ).
The rate of recovery of a3b4 receptors from the inhibition produced by the co-application of 100 mM ACh and 10 mM mecamylamine was determined by repeatedly administering 100 mM ACh at 5 min intervals (not shown). The data were ®t by an exponential function with a time constant for recovery of approximately 16 min. Although the induction of this form of inhibition was use dependent (see above), it did not appear that recovery could be enhanced by repeated agonist application. Figure 1 Concentration-response curves for the eect of mecamylamine on a3b4 and a3b4(b1TM2) receptors. (A) The concentration response relationship for mecamylamine's inhibition of the peak currents of a3b4 and a3b4(b1TM2) receptors when 100 mM ACh was co-applied with mecamylamine at the indicated concentrations. Data from each oocyte was normalized to that cell's response to 100 mM ACh alone. (B) Mecamylamine's residual eects on ACh responses of a3b4 and a3b4(b1TM2) receptors. The data plotted represent the responses to 100 mM ACh when it was applied 5 min after 100 mM ACh had been co-applied with mecamylamine at the indicated concentrations. Data were normalized to each cell's prior control response to 100 mM ACh alone. Each point represents the average normalized response of 4 ± 7 cells (+s.e.mean). Figure 2 Representative traces illustrating the eect of mecamylamine on a3b4 and a3b4(b1TM2) receptors. (A) The main ®gure shows an initial control response of an a3b4 -expressing oocyte to the application of 100 mM ACh and the diminished response when 100 mM ACh was co-applied with 300 nM mecamylamine. The insert shows the control and experimental responses scaled to the same amplitude to illustrate the accelerated peak of the mecamylamineinhibited current and the lack of any late-phase or relaxation current in the presence of mecamylamine. (B) The main ®gure shows an initial control response of an a3b4(b1TM2) expressing oocyte to the application of 100 mM ACh and the diminished response when 100 mM ACh was co-applied with 30 mM mecamylamine. The insert shows the responses scaled to the same amplitude to illustrate the accelerated peak of the mecamylamine-inhibited current and the presence of a small late-phase or relaxation current as the mecamylamine is washed from the chamber (arrow).
There was no signi®cant dierence in the amount of recovery over a 20 min period between cells that received four ACh applications at 5 min intervals and cells that received a single ACh application after a 20 min wash (data not shown).
Addition of neuronal b4TM2 sequence to muscle a1b1gd combinations promotes inhibition by mecamylamine Compared to neuronal nicotinic AChR, muscle-type nicotinic AChR are relatively insensitive to mecamylamine. As shown in Figure 3 , the average response to the co-application of 1 mM mecamylamine with 10 mM ACh to a1b1gd receptors was 83+6% of the amplitude of the control responses to 10 mM ACh alone. In contrast, the average response to the coapplication of 1 mM mecamylamine with 10 mM ACh to a1b1(b4TM2)gd receptors were reduced to 53+3% of the ACh controls, suggesting a nearly 3 fold increase in inhibition associated with the presence of the b4TM2 domain. After a 5 min washout of mecamylamine, control responses of a1b1gd receptors were within 5% of the original control amplitude, and the responses of a1b1(b4TM2)gd receptors had recovered to 83+6% of the control values.
The muscle b1TM2 can regulate the sensitivity of neuronal receptors to prolonged inhibition by nicotine Nicotine concentration-response experiments with a3b4 receptors showed maximal peak currents that were less than could be obtained with ACh (Figure 4) , suggesting that nicotine may only be a partial agonist for these receptors (Hussy et al., 1994) . However, our data also suggest that maximal responses to nicotine might be limited by a secondary antagonist activity, such as has been previously described for a4b2 receptors (de Fiebre et al., 1995) . At concentrations above 100 mM, responses to nicotine showed (A) The concentration-response relationship for nicotine's activation of currents in cells expressing a3b4 or a3b4(b1TM2) receptors. Data from each oocyte were ®rst normalized to that cell's response to 100 mM ACh alone and then adjusted for the ratio between the 100 mM ACh response and the ACh maximum, as measured in separate experiments (not shown) and as previously reported (Papke et al., 1997) . (B) Nicotine's residual eects on ACh responses of a3b4 and a3b4(b1TM2) receptors. The data plotted represent the responses to 100 mM ACh when it was applied 5 min after nicotine had been applied at the indicated concentrations. Data were normalized to each cell's prior control response to 100 mM ACh alone. Each point represents the average normalized response of 4 ± 7 cells (+s.e.mean). accelerated times to peak compared to the ACh control responses, and clearly evident relaxation from inhibition was seen when the nicotine was washed from the chamber ( Figure 5A ). Due to this fast washout of inhibitory eects, nicotine produced very little residual inhibition of a3b4 receptors ( Figure 4B ). Figure 5 Representative traces illustrating the eect of nicotine on a3b4 and a3b4(b1TM2) receptors. (A) Sample responses of a3b4 expressing cells to the application of nicotine at the indicated concentration, shown along with respective control ACh responses obtained 5 min earlier from the same cells. Note that at concentrations above 100 mM, nicotine fails to produce further increases in peak currents compared to ACh controls. However, nicotine does produce a protracted or late-phase current that can be associated with secondary inhibitory activity by this compound. Recovery from this inhibition is relatively rapid, as can be seen from the relaxation out of the inhibited state, clearly visible after the application of 1 mM nicotine. (B) The responses of an a3b4(b1TM2) receptor-expressing oocyte to the initial control application of 100 mM ACh (left-most trace), the application of 100 mM nicotine (middle trace), and a subsequent 100 mM ACh control response (right-most trace). Figure 6 The eects of mecamylamine and nicotine on a2b4 and a2b4(b1TM2) receptors. (A) The eects of 1 mM mecamylamine co-applied with 30 mM ACh on a2b4 and a2b4(b1TM2) receptors. Mecamylamine caused a strong inhibition of a2b3 receptor mediated-responses (P50.001), while there was no signi®cant eect of mecamylamine on a2b4(b1TM2) receptor mediatedresponses. (B) Control ACh responses measured 5 min after the application of 100 mM nicotine to a2b4 and a2b4(b1TM2) receptors. Nicotine caused a large inhibition of a2b4(b1TM2) receptor responses (P50.001) and a small decrease in a2b4 responses (P50.05). Each bar represents the average normalized responses of 4 ± 7 cells (+s.e.mean).
When nicotine was applied to a3b4(b1TM2) receptors, there was also an accelerated time to peak, even when nicotine was applied at relatively low concentrations. However, with this receptor subtype no relaxation from the inhibition was observed. In fact, the application of nicotine to a3b4(b1TM2) receptors produced profound inhibition that could be measured as decreases in the response to control ACh applications after a 5 min wash period ( Figure 4B ). The IC 50 for the residual inhibition of a3b4(b1TM2) receptors by nicotine was approximately 5 mM, while there was less than 50% residual inhibition of a3b4 receptors following the application of 1 mM nicotine (the highest concentration tested).
The rate of recovery of a3b4(b1TM2) receptors from the inhibition produced by the application of 30 mM nicotine was determined by repeatedly administering 100 mM ACh at 5 min intervals (not shown). The data was ®t by an exponential function with a time constant for recovery of approximately 51 min.
It is interesting to note that channel block by acetylcholine itself was apparently also enhanced in a3b4(b1TM2) receptors compared to the wild-type a3b4. This is suggested by the consistent observation that the peak responses of the a3b4(b1TM2) receptors to control applications of ACh were accelerated compared to responses of wild-type a3b4 receptors (Table 1) . Note in Figures 2 and 5 that the peak in the response of a3b4(b1TM2) receptors to the application of ACh occurred before solution exchange was completed. An increased inhibitory eect of ACh might also explain why the relative ecacy of nicotine compared to ACh appears increased in the a3b4(b1TM2) receptors ( Figure 4A ), such that compared to ACh, nicotine appears to be a full agonist for these receptors. When ACh was applied to a3b4(b1TM2) receptors at concentrations greater than 100 mM, subsequent ACh control responses were also decreased. The inhibition produced by the application of high (1 mM) ACh concentrations showed a time constant recovery of approximately 7 min (not shown).
The regulatory eects of TM2 sequence on receptor inhibition can be generalized to other neuronal receptor combinations
In order to determine whether the reciprocal eects of the beta subunit TM2 domain could be generalized to neuronal nicotinic AChR containing other alpha subunits, we coexpressed the a2 subunit with either b4 or b4(b1TM2). As shown in Figure 6 , 1 mM mecamylamine produced a strong inhibition of a2b4 receptors but not a2b4(b1TM2) receptors. Likewise, 5 min after the application of 100 mM nicotine, a2b4 receptors showed very little residual inhibition of control ACh responses, while the responses of a2b4(b1TM2) receptors were reduced to only 10% control levels, suggesting that they remained inhibited by approximately 90%. We were not able to obtain functional receptors from the co-expression of a4 with the b4(b1TM2) chimera. However, since the a4 and a2 subunits have identical sequence through the entire TM2 domain, it is likely that this important eect of the beta subunit TM2 in regulating sensitivity to mecamylamine and nicotine may be generalized for all beta subunit-containing nicotinic AChR.
The voltage dependence of inhibition by nicotine and mecamylamine
The requirement for channel activation prior to the onset of noncompetitive (i.e. use-dependent) inhibition confounds the estimation of the inhibitory eectiveness of mecamylamine when it is initially applied. Therefore, the measurement of residual inhibition may be taken as a more accurate estimate of the degree of drug equilibration during the complete course of the co-application. For that reason, we chose to measure the extent to which this residual inhibition was in¯uenced by the holding potential used when either mecamylamine or nicotine was applied. This measurement of the suppression of subsequent control responses had the additional advantage that the equivalent measurement could be made following the administration of nicotine to a3b4(b1TM2) receptors, giving an indication of inhibitory activity separate from the agonist activity of the drug.
When 300 nM mecamylamine was co-applied with ACh at a holding potential of 0 to 720 mV, subsequent control responses to ACh applied at the standard holding potential of 750 mV were suppressed by less than 20%. However, when 300 nM mecamylamine was co-applied with ACh at a holding potential of 760 to 780 mV, subsequent control responses to ACh applied at the standard holding potential of 750 mV were suppressed by more than 50%. This is in contrast to our previously reported observation that inhibition of a3b4 receptors by the bis-tetramethylpiperidine compound BTMPS was equally eective at both positive and negative holding potentials (Francis et al., 1998) .
In order to quantify the eect of voltage on inhibition by mecamylamine and nicotine, the data were transformed by the method of Woodhull (1973, see Methods) . Inhibition by mecamylamine showed an e-fold increase for a 42 mV change in voltage, suggesting that the binding site for mecamylamine would be approximately 60% into the membrane's electric ®eld. In contrast to this clear voltage dependence for mecamylamine, there was no apparent eect of voltage on the inhibition produced by nicotine, suggesting that like BTMPS, Figure 7 The voltage dependence of inhibition by mecamylamine and nicotine measured 5 min after application. The plot shows the amplitude of responses to control ACh applications when ACh was delivered 5 min after the application of drugs at the indicated voltages. Responses were normalized to the amplitude of the control response obtained 5 min before the application of the drugs. Mecamylamine (300 nM) was co-applied with 100 mM ACh to a3b4 expressing cells and 10 mM nicotine was applied to a3b4(b1TM2)-expressing cells. Mecamylamine and nicotine were applied at the indicated voltages, and the pre-and post-drug application control measurements were both made at the standard holding potential of 750 mV. Each point represents the average normalized response of 4 ± 5 cells (+s.e.mean).
it may be binding at sites external to the membrane's electric ®eld (Figure 7) .
Analysis of point mutations in TM2
The b1 and b4 subunits dier at only four amino acids within the sequence exchanged in our chimeras, the 4', 6', 7', and 10' TM2 residues. Therefore, we made point mutations which exchanged sequence at these locations. As shown in Figure 1 , compared to a3b4 wild-type receptors, a3b4(b1TM2) receptors show reduced sensitivity to mecamylamine as measured both at time of co-application and after a 5 min wash period. When the a3 subunit was co-expressed with either the b4(4'S), b4(7'A), or b4(10'T) mutants, the pattern of inhibition generally resembled that of a3b4 wild-type ( Figure 8A ). When a3 was co-expressed with b4(6'F), there was a trend toward decreased inhibition. However the responses of this receptor subtype were quite variable, and in fact, no signi®cant dierences were determined when compared to either wildtype or the full chimera. This would suggest that the 6' serine maybe important for long term inhibition by mecamylamine but that this modi®cation alone is not sucient to reproduce the eect seen with the TM2 chimera.
It has been previously reported that drugs that bind within the channel may interact with multiple levels of the transmembrane helix (Charnet et al., 1990) . The 10' residue is predicted to line the channel at the helical turn above the 6' residue, and while a partial eect was suggested for the 6' mutant, no signi®cant reversal of mecamylamine sensitivity was seen when the 10' residue was exchanged between the neuronal and muscle sequences. In fact, the 10' mutant showed a slight enhancement of the inhibition measured at 5 min when compared to control (P50.05).
To investigate the potential interactions between residues at the 6' and 10' sites, we made a double mutant b4(6'F10'T). Our data indicate that in fact the 10' threonine substitution did Figure 8 Analysis of point mutations. (A) The eects of 3 mM mecamylamine, co-applied with 100 mM ACh, to receptors containing a3 in combination with wild-type or mutant b4 subunits. (B) The eects of 10 mM nicotine applied to receptors containing a3 in combination with wild-type or mutant b4 subunits. For both (A) and (B), going from left to right, the beta subunits were wild-type b4 , b4 (4'S), b4 (6'F), b4 (7'A), b4 (10'T), b4 (6'F10'T), and b4(b1TM2). Note that the X axis label on the left-most graph is applicable for all of the plots. The zero time points represents the response during the drug application normalized to an initial control ACh response in the same cell. The 5 min bars represent the responses to control (100 mM) ACh applications obtained 5 min after the drug treatments, normalized to the earlier control response. Each bar represents the average normalized response of four cells (+s.e.mean). Statistical dierences were determined based on pairwise t-tests between the responses of mutant receptors compared to wild-type receptors and receptors containing TM2 chimeric beta subunits, as indicated.
enhance the eect obtained with the 6' phenylalanine substitution (Figure 8) , such that the double mutant showed diminished sensitivity both during the co-application response and as measured after a 5 min wash period (Figure 8 ) and was not statistically distinguishable from the full TM2 chimera.
The same series of mutants were examined for their sensitivity to nicotine as an agonist and as an antagonist. As shown in Figure 4 , the substitution of the b1TM2 domain into b4 increased both the agonist and antagonist eects of a 10 mM nicotine application. As shown in Figure 8B , the 6' serine to phenylalanine mutation increased the apparent agonist activity of nicotine (P5.01, pairwise t-test compared to wild-type receptors) but did not produce increased antagonism. The 10' single mutation also had a slight eect on nicotine's agonist activity (compared to ACh) but no signi®cant eect on residual inhibition compared to wild-type receptors. The 6'F10'T double mutation, however, produced signi®cant increases in both agonist and antagonist activity compared to wild-type (P50.01). Moreover, at the concentration tested, nicotine had an apparent agonist activity on the 6'F10'T double mutant that was also signi®cantly greater than that seen with the full TM2 chimera (Figure 8) .
We have previously reported that the beta subunit TM2 domain regulates the long term inhibition of neuronal nicotinic AChR produced by the use-dependent antagonist, BTMPS (Francis et al., 1998) . A comparison of the responses obtained from wild-type and TM2 chimeric receptors (Figure 9 ) illustrates this eect. Note that since the eects of BTMPS are use-dependent, co-application responses may in fact be larger than those recorded 5 min later (see for example, a3b4 wild-type). This is because channels must begin to open before they can be inhibited, so it is typical to see a brief spike in response to co-application . As shown in Figure 9 , mutations at the 6' position in either b1 or b4 are Figure 9 Point mutations regulate sensitivity to BTMPS. (A) The eects of 2 mM BTMPS, co-applied with 100 mM ACh, to receptors containing a3 in combination with wild-type or mutant b4 subunits. Going from left to right, the beta subunits were wildtype b4, b4 (4'S), b4 (6'F), b4 (7'A), b4 (10'T), b4 (6'F10'T), and b4(b1TM2). (B) The eects of 2 mM BTMPS, co-applied with 10 mM ACh, to receptors containing a1gd in combination with wild-type or mutant b1 subunits. Going from left to right, the beta subunits were wild-type b1, b1 (4'C), b1 (6'S), b1 (7'V), b1 (10'A), b1 (6'S10'A), and b1(b4TM2). Note that the X axis label on the left-most graph is applicable for all of the plots. For both (A) and (B) the responses at the zero time point represents the drug application normalized to an initial control ACh response in the same cell. The 5 min bars represent the responses to control (100 mM) ACh applications obtained 5 min after the drug treatments, normalized to the earlier control response. Each bar represents the average normalized response of 4 ± 6 cells (+s.e.mean). Statistical dierences were determined based on pairwise t-tests between the responses of mutant receptors compared to wild-type receptors and receptors containing TM2 chimeric beta subunits, as indicated.
essential for determining the dierence in sensitivity to BTMPS that exists between wild-type receptors and receptors containing TM2 chimeras. The data also suggest that substitution at the 10' site can further enhance the eect of the 6' mutation ( Figure 9 ).
Discussion
Due to its ability to block nicotinic activity in the brain with systemic administration, mecamylamine remains probably the most commonly used of all neuronal nicotinic AChR-speci®c inhibitors. Nonetheless, previous reports of mecamylamine's inhibitory activity in vitro have failed to reach a consensus for explaining this drug's mechanism of action. Mecamylamine was found to produce a voltage-dependent inhibition of rat cardiac parasympathetic ganglion nicotinic AChR with an IC 50 of 37 nM measured at 7120 mV (Fieber & Adams, 1991) . However, while Ascher et al. (1979) also found that the inhibition of parasympathetic neurons of the rat submandibular ganglion by mecamylamine showed a measurable voltage dependence, consistent with channel blocking activity, they further reported that inhibition was lessened when the drug was co-applied at high agonist concentrations. This observation was more consistent with a competitive mechanism for inhibition. Bertrand et al. (1990) reported that the eects of mecamylamine on heterologously expressed chick a4b2 receptors were persistent after the drug was co-applied with agonist, while application of the drug alone had no eect. In those experiments the inhibition measured during co-application with ACh was reported to be voltage independent.
Our data indicate that mecamylamine is a potent noncompetitive inhibitor of the heterologously expressed neuronal nicotinic AChR a3b4 subtype. Our experiments give an IC 50 for the inhibition of rat a3b4 receptor that is in very good agreement with the value reported by Cachelin & Rust (1995) of 190 nM as well as the value reported by Fieber & Adams (1991) for nicotinic AChR in rat cardiac ganglion neurons. In our experiments this inhibition appeared to be only slowly reversible for the wild-type a3b4 receptors, similar to the persistent inhibition of a4b2 receptors (Bertrand et al., 1990) . It may seem somewhat curious that the eects of mecamylamine on chick a4b2 receptors were reportedly voltage independent. However, in addition to the potential signi®cance of receptor subtype and species dierences, there were many procedural dierences between our experiments and those reported by Bertrand. Most notably, Bertrand reported voltage independence for instantaneous inhibition (i.e. during co-application), while we report a voltage dependence for the persistent inhibition measured 5 min after the antagonist was applied.
The inhibition of a3b4 receptors by mecamylamine in our experiments has the characteristics of open channel block and shows a voltage dependence similar to that of QX-222 for the block of muscle-type receptors (Neher & Steinbach, 1978) . Speci®cally, based on single channel kinetic analysis, QX-222 was calculated to show an e-fold change in potency for each 32 mV change in potential (Neher & Steinbach, 1978) , suggesting that the site of QX-222 binding was 78% through the membrane electric ®eld. Our data suggest that in a3b4 receptors mecamylamine binds to a site approximately 60% through the membrane's electric ®eld.
It has been proposed (Charnet et al., 1990 ) that binding of noncompetitive agents within the ion channel of the nicotinic AChR involves interactions with both a polar site and a hydrophobic site oriented along the axis of the membranespanning TM2 domain. Channel activation presumably controls the orientation of the TM2 helix so that these sites become accessible to inhibitors from the extracellular surface. The voltage dependence of inhibition would then be related to the depth of the polar site relative to the voltage drop within the channel. Site-directed mutagenesis studies indicated that the binding of QX-222 is associated with an inner polar site corresponding to the 6' residue of TM2. It is likely that mecamylamine associates with the homologous site in neuronal a3b4 receptors, such that the primary polar interaction at the 6' site is further stabilized by the hydrophobic character of the 10' ring. In wild-type muscle receptors (a1b1gd), which are relatively insensitive to mecamylamine, the b1 subunit limits the polar nature of this site with a phenylalanine residue at the 6' position. In wild-type a3b4 receptors there would be serine residues present at this site in all ®ve subunits. In the chimeric a3b4(b1TM2) receptors, at least two residues at this location are mutated to phenylalanine. This change in the character of the inner polar site in multiple subunits could easily account for the observed 200 fold decrease in mecamylamine potency. While inclusion of the b4TM2 sequence into the muscle b1 subunit increases the transient inhibition produced by mecamylamine, the relatively modest eect obtained may be related to the fact that the chimeric receptors were likely to be changed at a single site in the pentameric complex.
The chimeric a3b4(b1TM2) receptors appear to have faster kinetics of deactivation than the wild-type receptors, suggesting a decrease in the net P open during an ACh-evoked response.
This decreased P open would subsequently reduce the likelihood of use-dependent eects. However, the relative change in the ratio of net charge to peak current for chimeric receptors, compared to wild-type, is much less than the decrease we observe in mecamylamine potency. Moreover, the greatly increased rate of recovery from mecamylamine eects in the chimeric receptor suggests that these mutations have direct eects at the mecamylamine binding site, and are not just reducing the probability of block.
The activity pro®le of nicotine for the various neuronal AChR is in¯uenced by subtype speci®c competitive and noncompetitive eects. Consistent with reports by others (Hussy et al., 1994) , our experiments indicate that nicotine's ecacy for the activation of a3b4 receptors is limited, at least in part, by readily reversible antagonist activity. While it might be argued that the increased inhibition of a3b4(b1TM2) receptors by agonist might represent accelerated desensitization, it would also be consistent with increases in secondary inhibition by the agonists themselves. Note that the wild-type a3b4 receptors show clear indication of channel block (or other form of noncompetitive inhibition) by nicotine, with a suppression of the current response during a nicotine application that is use-dependent and concentration-dependent in its onset. This would suggest that the most parsimonious explanation of the chimeric receptor's prolonged inhibition may be that nicotine is binding to some inhibitor site on both the wild-type and the chimeric receptors but with enhanced anity for the chimeric receptors, most probably due to a decreased o-rate.
The basic concept of desensitization is that the desensitized receptor is in a non-activatable state that can persist in the absence of bound agonist, such that a new agonist-binding event is unlikely to open the channel. However, we see that the recovery from inhibition produced by the two agonists ACh and nicotine proceeds at very dierent rates (7 min and 51 min, respectively). To interpret this in terms of desensitization would require that these two drugs produced distinctly dierent forms of desensitization. This is inconsistent with the accepted concept of the Markov-type behaviour of ion channels, and would require that the channel retained some memory of which agonist produced the conformational transition to the desensitized state. Again, the more parsimonious explanation is that during the onset of inhibition, the agonist (either nicotine or ACh) binds at a speci®c site, not associated with activation, and that recovery from inhibition occurs at a rate derived by the dissociation rate for the speci®c ligand from that inhibitory site.
It is unclear whether the actual binding site for nicotine is likely to be within the channel, or as proposed for BTMPS, somewhere in the extracellular part of the protein, with the anity for nicotine regulated by the translation of gating movements through the TM2 domain. The apparent lack of voltage-dependence for nicotine's inhibitory eect would argue against the idea that nicotine may be binding directly within the channel. However, the mutational analysis indicates that the inhibitory activity of nicotine may require both the 10' and the 6' substitutions. These mutations eectively create a new polar ring at the 10' position, corresponding to the next level up on the helical wheel from where mecamylamine appears to be binding. There will be an enhanced polar quality to the intermediate ring in a3b4(b1TM2) receptors and a highly hydrophobic site at the 6' position. It may be the case that these changes produce a binding site for nicotine that is con®gured so that nicotine preferentially binds with the relatively hydrophobic pyridine ring of nicotine oriented toward the intracellular end of the channel at the 6' ring, while the charged nitrogen of nicotine may interact with the more polar residues at the 10' position in TM2. A speci®c interaction of nicotine at this intermediate polar site would correspond to a reduced voltage dependence for the nicotineinduced inhibition compared to the eects of mecamylamine. It may be the case that our measurements were not suciently sensitive to resolve what could have been a relatively small voltage dependence.
Alternatively, nicotine may not be binding to the 10' site. Instead, what we observed may be due to how the speci®c con®guration of polar sites within TM2 aect the translation of conformational change to other parts of the receptor, including an inhibitory site for nicotine that is above the membrane's electric ®eld. Our previous study of bis-tetramethylpiperidine inhibitors demonstrated a similar eect, such that the neuronal beta subunit TM2 domain was important for the translation of the conformational changes associated with channel gating, regulating the accessibility or anity of a binding site for the selective neuronal nicotinic AChR inhibitor BTMPS. The BTMPS binding site was outside of the membrane's electric ®eld, and therefore unlikely to be located within the chimeric domain itself. While in the present study we demonstrate that the neuronal beta TM2 can also directly control the selectivity of the ganglionic blocker mecamylamine for neuronal nicotinic AChR by providing a binding site within TM2 that appears to be analogous to the binding site for local anaesthetics to the muscle ± type AChR, it may be the case that nicotine produces inhibitory eects in a manner more analogous to the inhibition produced by BTMPS. However, if this is the case, then it would suggest that BTMPS and nicotine bind with high anity to qualitatively dierent sites, since their use-dependent inhibitory eects have opposite requirement for TM2 sequence.
In conclusion, the present study provides new insight into how noncompetitive inhibition by both agonists and antagonists share a dependence on speci®c sequence in a channel forming domain. Our data support the hypothesis that inhibition can occur, either through direct binding to sites within the channel or alternatively, through allosteric interactions associated with the translation of conformational change regulated by channel gating. The observation that conformational information may be transmitted from TM2 to a remote site is likely to be of general signi®cance for our understanding of protein structure and function. Moreover, since the nicotinic agents presently in clinical development typically have mixed agonist/antagonist eects, our data may suggest ways to optimize the development of these drugs for speci®c therapeutic applications. Through the identi®cation of the inhibitory mechanisms for speci®c drugs, we may seek to achieve the most eective balance of selectivity for activation and inhibition of the various neuronal nicotinic AChR subtypes.
